CNAT was initiated today by Oppenheimer at Outperform with a $16 price target, hence the positive move.
I own some CNAT. But be careful, or be ready if you are buying at some point....they expect news to be out regarding their FDA stage whatever during the second quarter of this year....for better or worse.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.